A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes

A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes

Clinical Nutrition

10.1016/j.clnu.2013.01.012

https://doi.org/10.1016/j.clnu.2013.01.012

Asal Ataie-Jafari, Seng-Cheong Loke, Asmah B. Rahmat, Bagher Larijani, Farzaneh Abbasi, Melvin K. S. Leow, Zaitun Yassin

C-Peptide, diabetes mellitus, Type 1, Hydroxycholecalciferols, Insulin-secreting cells, Iran, Randomized controlled trial

28 January 2013

Ataie-Jafari A, Loke SC, Rahmat AB, et al. A randomized placebo-controlled trial of alphacalcidol on the preservation of beta cell function in children with recent onset type 1 diabetes. Clin Nutr. 2013;32(6):911‐917. doi:10.1016/j.clnu.2013.01.012

Background & aims: This participant-blinded parallel-group randomized placebo-controlled study demonstrated that alfacalcidol (vitamin D analogue) preserves beta cell function in newly diagnosed type 1 diabetes (T1DM) in children. Methods: Subjects from outpatient clinic were randomized to intervention and control groups. Inclusion: (1) age 8e15, (2) T1DM, (3) duration

http://creativecommons.org/licenses/by-nc-nd/4.0/

The study was run using internal funding from the Endocrinology and Metabolism Research Center (EMRC), Tehran University of Medical Sciences.

https://astaroar.ripplewerkz.co/communities-collections/articles/15734

0261-5614
1532-1983

Institute for Human Development and Potential